Expression of the TMPRSS2:ERG fusion gene predicts cancer recurrence after surgery for localised prostate cancer
暂无分享,去创建一个
J. Trachtenberg | S. Srivastava | L. Klotz | S. Narod | A. Seth | L. Sugar | D. Loblaw | R. Nam | A. Stanimirovic | R K Nam | L Sugar | W Yang | S Srivastava | L H Klotz | L-Y Yang | A Stanimirovic | E Encioiu | M Neill | D A Loblaw | J Trachtenberg | S A Narod | A Seth | L-Y Yang | Wenyi Yang | W. Yang | E. Encioiu | M. Neill | W. Yang | W. Yang | W. Yang | Yang Ly | W. Yang
[1] J Cuzick,et al. Duplication of the fusion of TMPRSS2 to ERG sequences identifies fatal human prostate cancer , 2008, Oncogene.
[2] Jianfeng Xu,et al. Multiple genomic alterations on 21q22 predict various TMPRSS2/ERG fusion transcripts in human prostate cancers , 2007, Genes, chromosomes & cancer.
[3] Yao-Tseng Chen,et al. Gene fusions between TMPRSS2 and ETS family genes in prostate cancer: frequency and transcript variant analysis by RT-PCR and FISH on paraffin-embedded tissues , 2007, Modern Pathology.
[4] Y Pawitan,et al. TMPRSS2:ERG gene fusion associated with lethal prostate cancer in a watchful waiting cohort , 2007, Oncogene.
[5] M. Rubin,et al. Morphological features of TMPRSS2–ERG gene fusion prostate cancer , 2007, The Journal of pathology.
[6] R. Eeles,et al. Diversity of TMPRSS2-ERG fusion transcripts in the human prostate , 2007, Oncogene.
[7] J. Brooks,et al. A variant TMPRSS2 isoform and ERG fusion product in prostate cancer with implications for molecular diagnosis , 2007, Modern Pathology.
[8] S. Leung,et al. Frequency of the TMPRSS2:ERG gene fusion is increased in moderate to poorly differentiated prostate cancers , 2007, Journal of Clinical Pathology.
[9] L. Klotz,et al. Expression of TMPRSS2:ERG gene fusion in prostate cancer cells is an important prognostic factor for cancer progression , 2007, Cancer biology & therapy.
[10] D. Yee,et al. Disrupting insulin-like growth factor signaling as a potential cancer therapy , 2007, Molecular Cancer Therapeutics.
[11] Michael Ittmann,et al. Expression of variant TMPRSS2/ERG fusion messenger RNAs is associated with aggressive prostate cancer. , 2006, Cancer research.
[12] J. Tchinda,et al. TMPRSS2:ERG fusion-associated deletions provide insight into the heterogeneity of prostate cancer. , 2006, Cancer research.
[13] I. Panagopoulos,et al. Confirmation of the high frequency of the TMPRSS2/ERG fusion gene in prostate cancer. , 2006, Genes, chromosomes & cancer.
[14] A. Seidman. Systemic treatment of breast cancer. Two decades of progress. , 2006, Oncology.
[15] J. Tchinda,et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. , 2006, Science.
[16] A. Seth,et al. ETS transcription factors and their emerging roles in human cancer. , 2005, European journal of cancer.
[17] J. Richie. Radical prostatectomy vs watchful waiting in early prostate cancer , 2005, BJU international.
[18] Hans Garmo,et al. Radical Prostatectomy versus Watchful Waiting in Early Prostate Cancer , 2011 .
[19] Gurkamal Chatta,et al. Surrogate end point for prostate cancer-specific mortality after radical prostatectomy or radiation therapy , 2003 .
[20] Ming-Hui Chen,et al. Surrogate end point for prostate cancer-specific mortality after radical prostatectomy or radiation therapy. , 2003, Journal of the National Cancer Institute.
[21] A. Evans,et al. Delay in surgical therapy for clinically localized prostate cancer and biochemical recurrence after radical prostatectomy. , 2003, The Canadian journal of urology.
[22] E. Bergstralh,et al. Outcomes for men with clinically nonmetastatic prostate carcinoma managed with radical prostactectomy, external beam radiotherapy, or expectant management , 2001, Cancer.
[23] R. Hubert,et al. Catalytic cleavage of the androgen-regulated TMPRSS2 protease results in its secretion by prostate and prostate cancer epithelia. , 2001, Cancer research.
[24] L. Hood,et al. Prostate-localized and androgen-regulated expression of the membrane-bound serine protease TMPRSS2. , 1999, Cancer research.
[25] A W Partin,et al. Natural history of progression after PSA elevation following radical prostatectomy. , 1999, JAMA.
[26] J. Hanley,et al. Competing risk analysis of men aged 55 to 74 years at diagnosis managed conservatively for clinically localized prostate cancer. , 1999, JAMA.
[27] J. Hanley,et al. Competing Risk Analysis of Men Aged 55 to 74 Years at Diagnosis Managed Conservatively for Clinically Localized Prostate Cancer , 1998 .
[28] N. Kyprianou,et al. Incidence of apoptosis and cell proliferation in prostate cancer: Relationship with TGF‐β1 and bcl‐2 expression , 1996, International journal of cancer.
[29] J. Oesterling,et al. Radical prostatectomy for clinically localized prostate cancer: long-term results of 1,143 patients from a single institution. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[30] A. Partin,et al. Cancer control and quality of life following anatomical radical retropubic prostatectomy: results at 10 years. , 1994, The Journal of urology.
[31] P. Keane,et al. Eosinophilic vasculitis (Churg-Strauss syndrome) involving the urethra. , 1994, British journal of urology.
[32] P. Walsh. Results of conservative management of clinically localized prostate cancer. , 1994, The Journal of urology.
[33] B. Wasylyk,et al. The Ets family of transcription factors. , 1993, European journal of biochemistry.